Last updated on February 2018

MabionCD20 Compared to MabThera in Lymphoma Patients


Brief description of study

The aim of the study is to demonstrate the high level of biosimilarity between MabionCD20 (MABION SA) and the reference product: MabThera (rituximab by Hoffman-La Roche) in patients with CD20-positive diffuse large B-cell lymphoma.

Detailed Study Description

Patients who meet criteria for participation in this study receive 8 intravenous infusions of MabionCD20 or MabThera 21 days interval in combination with standard dosage regimen of CHOP. The duration of the study is 12 months. The treatment and observation period will last 26 weeks starting from Day 1, until Week 26 - one month after last IMP infusion.

Clinical Study Identifier: NCT02617485

Find a site near you

Start Over

University Clinical Center Banja Luka

Banja Luka, Bosnia and Herzegovina
  Connect »

University Clinical Center Sarajevo

Sarajevo, Bosnia and Herzegovina
  Connect »

University Clinical Center Tuzla

Tuzla, Bosnia and Herzegovina
  Connect »

General Hospital Zenica

Zenica, Bosnia and Herzegovina
  Connect »

GH "dr.Josip Bencevic"

Slavonski Brod, Croatia
  Connect »

CH Merkur

Zagreb, Croatia
  Connect »

CHC Zagreb

Zagreb, Croatia
  Connect »

HEMA

Tibilisi, Georgia
  Connect »